Dr. Antonio Lupia
Department of Life and Environmental Sciences, University of Cagliari, Cagliari, Sardegna, Italy
'%3e%3cpath%20d='M22.1642%2019.0924C21.7317%2018.068%2021.1041%2017.1375%2020.3163%2016.3527C19.5309%2015.5656%2018.6006%2014.9381%2017.5766%2014.5048C17.5674%2014.5002%2017.5582%2014.4979%2017.5491%2014.4933C18.9774%2013.4616%2019.9059%2011.7811%2019.9059%209.88504C19.9059%206.74408%2017.3611%204.19922%2014.2201%204.19922C11.0792%204.19922%208.53429%206.74408%208.53429%209.88504C8.53429%2011.7811%209.46282%2013.4616%2010.8912%2014.4956C10.882%2014.5002%2010.8728%2014.5025%2010.8636%2014.5071C9.83652%2014.9404%208.91487%2015.5617%208.1239%2016.355C7.33685%2017.1404%206.70933%2018.0707%206.276%2019.0947C5.85031%2020.0972%205.62072%2021.172%205.59967%2022.2609C5.59905%2022.2853%205.60335%2022.3097%205.61229%2022.3325C5.62123%2022.3553%205.63465%2022.376%205.65174%2022.3935C5.66883%2022.4111%205.68926%2022.425%205.71182%2022.4345C5.73437%2022.444%205.7586%2022.4489%205.78308%2022.4489H7.15868C7.25956%2022.4489%207.3398%2022.3686%207.3421%2022.2701C7.38795%2020.5001%208.09868%2018.8425%209.35506%2017.5861C10.655%2016.2862%2012.3814%2015.5709%2014.2201%2015.5709C16.0588%2015.5709%2017.7852%2016.2862%2019.0852%2017.5861C20.3415%2018.8425%2021.0523%2020.5001%2021.0981%2022.2701C21.1004%2022.3709%2021.1807%2022.4489%2021.2815%2022.4489H22.6571C22.6816%2022.4489%2022.7058%2022.444%2022.7284%2022.4345C22.751%2022.425%2022.7714%2022.4111%2022.7885%2022.3935C22.8056%2022.376%2022.819%2022.3553%2022.8279%2022.3325C22.8369%2022.3097%2022.8412%2022.2853%2022.8406%2022.2609C22.8176%2021.165%2022.5907%2020.0989%2022.1642%2019.0924ZM14.2201%2013.8284C13.1678%2013.8284%2012.1773%2013.418%2011.4322%2012.6729C10.6871%2011.9278%2010.2767%2010.9374%2010.2767%209.88504C10.2767%208.83271%2010.6871%207.84227%2011.4322%207.09715C12.1773%206.35204%2013.1678%205.94165%2014.2201%205.94165C15.2724%205.94165%2016.2629%206.35204%2017.008%207.09715C17.7531%207.84227%2018.1635%208.83271%2018.1635%209.88504C18.1635%2010.9374%2017.7531%2011.9278%2017.008%2012.6729C16.2629%2013.418%2015.2724%2013.8284%2014.2201%2013.8284Z'%20fill='%238590A2'/%3e%3c/g%3e%3c/svg%3e)
Co-authors
Following
Followers
Research Focus & Metrics
Explore full metrics on Scilit
Academic Career Length
11Years (2016-Present)
(Calculated once Scilit publication data is synced: current year − year of first publication + 1)
Representative Publications
View All Publications1 January 2020 in European Journal of Medicinal Chemistry
Journal Article
DBDonatella Bagetta
Donatella Bagetta
Annalisa MarucaAntonio Lupia
Francesco MesitiRCRaffaella Catalano
Raffaella Catalano
Roberta Rocca +7
1 November 2019 in European Journal of Medicinal Chemistry
Journal Article
Annalisa MarucaRCRaffaella Catalano
Raffaella CatalanoDBDonatella Bagetta
Donatella Bagetta
Francesco MesitiFAFrancesca Alessandra Ambrosio
Francesca Alessandra Ambrosio
Antonio Lupia +7
13 October 2017 in Molecular Cancer
Journal Article
EIEnrico Iaccino
Enrico IaccinoSMSelena Mimmi
Selena MimmiVDVincenzo Dattilo
Vincenzo DattiloFMFabiola Marino
Fabiola Marino
Patrizio CandeloroGSGiuseppe Scala
Giuseppe Scala
+10
Tumor-derived exosomes (TDEs) play a pivotal role in tumor establishment and progression, and are emerging biomarkers for tumor diagnosis in personalized medicine. To date, there is a lack of efficient technology platforms for exosome isolation and characterization. Multiple myeloma (MM) is an incurable B-cell malignancy due to the rapid development of drug-resistance. MM-released exosomes express the immunoglobulin B-cell receptor (Ig-BCR) of the tumor B-cells, which can be targeted by Idiotype-binding peptides (Id-peptides). In this study, we analyzed the production of MM-released exosomes in the murine 5T33MM multiple myeloma model as biomarkers of tumor growth. To this end, we selected Id-peptides by screening a phage display library using as bait the Ig-BCR expressed by 5T33MM cells. By FACS, the FITC-conjugated Id-peptides detected the MM-released exosomes in the serum of 5T33MM-engrafted mice, levels of which are correlated with tumor progression at an earlier time point compared to serum paraprotein. These results indicate that Id-peptide-based recognition of MM-released exosomes may represent a very sensitive diagnostic approach for clinical evaluation of disease progression.
Journal Article
ACAdriana Coricello
Adriana CoricelloFrancesco MesitiAntonio LupiaAnnalisa MarucaSAStefano Alcaro
Stefano AlcaroThe mechanisms of inflammation and cancer are intertwined by complex networks of signaling pathways. Dysregulations in the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway underlie several pathogenic conditions related to chronic inflammatory states, autoimmune diseases and cancer. Historically, the potential application of JAK inhibition has been thoroughly explored, thus triggering an escalation of favorable results in this field. So far, five JAK inhibitors have been approved by the Food and Drug Administration (FDA) for the treatment of different diseases. Considering the complexity of JAK-depending processes and their involvement in multiple disorders, JAK inhibitors are the perfect candidates for drug repurposing and for the assessment of multitarget strategies. Herein we reviewed the recent progress concerning JAK inhibition, including the innovations provided by the release of JAKs crystal structures and the improvement of synthetic strategies aimed to simplify of the industrial scale-up.
8 August 2018 in PeerJ
Journal Article
DCDomenica M. Corigliano
Domenica M. Corigliano
RSRiyaz Syed
Riyaz Syed
SMSebastiano Messineo
Sebastiano Messineo
Antonio LupiaRPRahul Patel
Rahul Patel
Antonio Brunetti +7
Background: Thiazolidinediones (TZDs), also called glitazones, are five-membered carbon ring molecules commonly used for the management of insulin resistance and type 2 diabetes. Recently, many prospective studies have also documented the impact of these compounds as anti-proliferative agents, though several negative side effects such as hepatotoxicity, water retention and cardiac issues have been reported. In this work, we synthesized twenty-six new TZD analogues where the thiazolidinone moiety is directly connected to an N-heterocyclic ring in order to lower their toxic effects. Methods: By adopting a widely applicable synthetic method, twenty-six TZD derivatives were synthesized and tested for their antiproliferative activity in MTT and Wound healing assays with PC3 (prostate cancer) and MCF-7 (breast cancer) cells. Results: Three compounds, out of twenty-six, significantly decreased cellular viability and migration, and these effects were even more pronounced when compared with rosiglitazone, a well-known member of the TZD class of antidiabetic agents. As revealed by Western blot analysis, part of this antiproliferative effect was supported by apoptosis studies evaluating BCL-xL and C-PARP protein expression. Conclusion: Our data highlight the promising potential of these TZD derivatives as anti-proliferative agents for the treatment of prostate and breast cancer.
Journal Article
CTChiara Tarantelli
Chiara TarantelliAntonio LupiaASAnastasios Stathis
Anastasios Stathis
Francesco BertoniThe activation of the PI3K/AKT/mTOR pathway is a main driver of cell growth, proliferation, survival, and chemoresistance of cancer cells, and, for this reason, represents an attractive target for developing targeted anti-cancer drugs. There are plenty of preclinical data sustaining the anti-tumor activity of dual PI3K/mTOR inhibitors as single agents and in combination in lymphomas. Clinical responses, including complete remissions (especially in follicular lymphoma patients), are also observed in the very few clinical studies performed in patients that are affected by relapsed/refractory lymphomas or chronic lymphocytic leukemia. In this review, we summarize the literature on dual PI3K/mTOR inhibitors focusing on the lymphoma setting, presenting both the three compounds still in clinical development and those with a clinical program stopped or put on hold.
About Me
Antonio Lupia was born in Catanzaro (Italy) on March 7th, 1989. In 2015 he received the degree in Pharmacy at the University "Magna Græcia" of Catanzaro, discussing an experimental thesis titled "Identification of new selective bioactive ligands for phospho-tyrosine-phosphatase 1B", under the supervision of Prof. Anna Artese and the professor Gerhard Wolber, Frëie University of Berlin. In 2019, at the University Magna Græcia of Catanzaro, he reached the PhD degrees in Life Sciences defending a thesis entitled "Molecular modelling of epitopes recognised by neoplastic B-cells in Chronic Lymphocytic Leukemia", also receiving the Paul Ehrlich Euro-PhD award.
Dr Antonio Lupia has been deeply involved in in-silico computational analysis of epitopic reactivity of tumour B cell clones in Chronic Lymphocytic Leukaemia (CLL). During the PhD training program, he spent a period at the Institute of Oncology Research of Bellinzona where used in-silico computational methods for the studying of tumour targets for promising ligands, under the supervisors of Dr Francesco Bertoni and Dr Eugenio Gaudio. Furthermore, thanks to Dr Luciano Cascione, he acquired knowledge of new bioinformatics tools.
To date, he joined Net4Science academic spin-off based in Catanzaro, where he works as a computational chemist. The scientific interests concern the application of new computational methods for the study of intermolecular drug-receptor interactions and the design of potential anticancer drugs.